NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS ...Middle East

CAMBRIDGE, Mass., Feb. 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional...

Hence then, the article about neurosense announces statistically significant 65 reduction in risk of death and greater than 14 month median survival benefit with primec in als was published today ( Wednesday 18/02/2026 - 05:13 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS )

Also on site :

• Ann Godoff, Penguin Press Founder and Editor, Dies at 76
• How Lisa Rinna's Mother 'Survived' a Brutal Serial Killer Attack
• Forget Normal Cases – PITAKA’s Aaron Button Lets Your S26 Do Things Phones Alone Can’t